What Mestastop Solutions does

Mestastop Solutions is a Bengaluru-based, privately held biotech startup founded in 2018 that focuses on cancer metastasis — the spread of cancer cells from a primary tumor to secondary organs, which is a leading cause of cancer-related death. The company develops proprietary in vitro, in vivo, and patient ex-vivo platforms to address both metastasis drug discovery and predictive diagnostics. Its core work centers on identifying and blocking cancer cells capable of spreading, using two repurposed drugs to target metastasis in colorectal cancer patients in a planned Phase II clinical trial.

Mestastop's technology stack comprises three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze a 30-step metastasis process to surface specific cells capable of disseminating to secondary organs. The company has secured regulatory approval to launch a Phase II trial enrolling at least 60 post-surgery colorectal cancer patients in a two-year treatment regimen, with results expected in approximately three years. Cumulative disclosed funding across three rounds (2020–2023) is approximately $714,000, with backers including Mumbai Angels, IIMA Ventures, IKP Knowledge Park, 92 Angels, and Malpani Ventures. The company is co-founded by Debabani Roy Chowdhury and Arnab Roy Chowdhury.

The business model is pre-commercial: Mestastop is a clinical-stage biotech with no disclosed pricing, no paying customers, and no product revenue. Its go-to-market motion is enterprise-field-sales and regulatory-driven, dependent on clinical trial execution, future pharma partnerships, or licensing of its repurposed-drug assets and diagnostic platforms. Geographic footprint is currently limited to Bengaluru, India, with 11–50 employees and no subsidiaries or institutional parent identified in the data.

Name

Mestastop Solutions

Website

https://mestastop.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Mestastop Solutions is a Bengaluru-based clinical-stage biotech that uses three proprietary platforms (METAssay, METSCAN, METVivo) to identify and block metastasis-causing cancer cells, advancing two repurposed drugs into a Phase II colorectal cancer trial.

Ownership category

akta.pro rank

Product category

Oncology Drug Discovery

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Medical Oncology (HLAKAFAB)

Keywords

• Cancer metastasis research
• Drug discovery platforms
• Predictive diagnostics
• In vitro assays
• Clinical trials

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Go-to-market motion1 record

Core offering

Mestastop Solutions develops proprietary in vitro, in vivo, and patient ex-vivo platforms that recreate and analyze the 30-step metastasis process to identify and block cancer cells capable of spreading to secondary organs. The company is preparing a Phase II clinical trial with two repurposed drugs targeting metastasis in post-surgery colorectal cancer patients, with plans to enroll at least 60 patients in a two-year treatment regimen.

Product overview

Mestastop Solutions offers a unified platform comprised of three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze the 30-step metastasis process to identify and block specific cancer cells capable of spreading to secondary organs. The company is developing two repurposed drugs for a Phase II clinical trial targeting metastasis in colorectal cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

• METAssay One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.
• METSCAN One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.
• METVivo One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Hummingbird Bioscience: Precision oncology biotech using proprietary platforms to discover and develop antibody and small-molecule therapeutics against high-value cancer targets. Comparable in platform-driven discovery approach and clinical-stage positioning.
• Lantern Pharma: AI-driven oncology drug development company with a focus on repurposed and accelerated drug development programs, including in metastatic indications. Highly comparable in its use of repurposed drugs and platform-enabled oncology development.
• Accutar Biotech: AI- and structure-based drug discovery company focused on oncology, using computational platforms to identify novel candidates. Comparable in platform-driven oncology drug discovery, although at a more advanced clinical stage.
• Inzen Therapeutics: Early-stage biotech focused on developing therapeutics targeting the metastatic cascade. Highly comparable to Mestastop in scientific focus (metastasis biology), stage, and small-team operating model.

Broad incumbents

• Guardant Health: Established oncology precision medicine company offering liquid biopsy and molecular diagnostics to identify and monitor cancer, including metastatic disease. A broad incumbent in cancer diagnostics that validates the market Mestastop's predictive diagnostics platform targets.
• Tempus AI: AI-enabled precision medicine company with extensive oncology data, diagnostics, and drug-discovery capabilities. A broad incumbent in oncology data and diagnostics that contextualizes Mestastop's platform approach at scale.
• Foundation Medicine: Major oncology molecular diagnostics company (a Roche subsidiary) providing comprehensive genomic profiling of tumors to inform cancer treatment. A broad incumbent whose cancer-profiling capabilities overlap with Mestastop's predictive diagnostics positioning.

Emerging players

• SEngine Precision Medicine: Functional diagnostics company that uses patient-derived tumor cells to test drug sensitivity and guide oncology treatment selection. Comparable in patient ex-vivo testing methodology and cancer-drug matching approach.
• Notable Labs: Functional precision medicine platform that tests cancer drugs (including repurposed drugs) against patient-derived cancer cells to predict response. Comparable in combining ex-vivo patient-cell testing with drug repurposing in oncology.
• Repurpose.AI: AI-driven drug repurposing platform with applications across oncology. Comparable through the shared repurposed-drug development model targeting cancer indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/mestastop

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mestastop Solutions